1-2 of 2
Robert Gut
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy

Clinical Trials & Observations
Annette von Drygalski, Esteban Gomez, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan U. Lattimore, Frank W. G. Leebeek, Wolfgang A. Miesbach, Michael Recht, Robert Gut, Ricardo Dolmetsch, Paul E. Monahan, Sandra Le Quellec, Steven W. Pipe
Journal: Blood Advances
Blood Adv (2023) 7 (19): 5671–5679.
https://doi.org/10.1182/bloodadvances.2022008886
Published: 2023
Includes: Supplemental data
Journal Articles

Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B

Annette Von Drygalski, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan Lattimore, Frank W. G. Leebeek, Wolfgang Miesbach, Michael Recht, Alison Long, Robert Gut, Eileen K. Sawyer, Steven W. Pipe
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3241–3247.
https://doi.org/10.1182/bloodadvances.2019000811
Published: 2019
Includes: Supplemental data